About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Research Beam Model: Research Beam Product ID: 175961 2500 USD New
Cystic Fibrosis Market in Europe 2015-2019
 

Cystic Fibrosis Market in Europe 2015-2019

Cystic Fibrosis Market in Europe 2015-2019

Category : Healthcare
Published On : February  2015
Pages : 113

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About Cystic Fibrosis

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth.  The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.

TechNavio's analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:

• Small Molecules
• Biologics

TechNavio's report, Cystic Fibrosis Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors
• Actavis
• F. Hoffmann-La Roche
• Gilead Sciences
• Novartis
• Vertex Pharmaceuticals

Other Prominent Vendors
 • Abbott
• Anthera Pharmaceuticals
• Arcturus Therapeutics 
• Boehringer Ingelheim 
• Chiesi Farmaceutici
• Corbus Pharmaceuticals
• Genzyme
• Insmed
• Johnson & Johnson 
• Merck Sharp & Dohme
• Neovii Biotech
• Novo Nordisk
• PharmaSwiss 
• Pharmaxis 
• Proteostasis Therapeutics
• PTC Therapeutics
• United Medical
• Venus Remedies 

Market Driver
• Unmet Needs
• For a full, detailed list, view our report

Market Challenge
• High Cost of Treatments
• For a full, detailed list, view our report

Market Trend
• Rise in Public Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Product Profiles

05.1.1 Zenpep

05.1.2 Colomycin/Colobreathe

05.1.3 Pulmozyme

05.1.4 Cayston

05.1.5 TOBI/TOBI Podhaler

05.1.6 Kalydeco

06. Introduction

07. Disease Overview

07.1 Understanding the Disease

07.2 Pathophysiology

07.3 Epidemiology

07.3.1 Global

07.3.2 UK

07.4 Diagnosis

07.4.1 Carrier Testing

07.4.2 Antenatal Testing

07.4.3 Newborn Screening

07.4.4 Other Tests

07.5 Manifestations of Cystic Fibrosis

07.6 Economic Burden

08. Pipeline Portfolio

09. Market Landscape

09.1 Market Overview

09.2 Market Size and Forecast

09.3 Five Forces Analysis

10. Segmentation of Cystic Fibrosis Market in Europe by Molecule Type

10.1 Biologics

10.1.1 Enzymes

10.2 Small Molecules

10.2.1 CFTR Modulators

10.2.2 Antibiotics

11. Segmentation of Cystic Fibrosis Market in Europe by Route of Administration

11.1 Oral

11.2 Parenteral

11.3 Topical

12. Segmentation of Cystic Fibrosis Market in Europe by Dosage Form

12.1 Solid

12.2 Liquid

13. Key Leading Countries

13.1 UK

13.2 France

13.3 Italy

13.4 Germany

13.5 Spain

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Market Share Analysis 2014

21.2.1 Actavis

21.2.2 F. Hoffmann-La Roche

21.2.3 Gilead Sciences

21.2.4 Novartis

21.2.5 Vertex Pharmaceuticals

21.3 Other and Future Prominent Vendors

22. Key Vendor Analysis

22.1 Actavis

22.1.1 Key Facts

22.1.2 Business Description

22.1.3 Business Segmentation

22.1.4 Business Segmentation by Revenue 2012 and 2013

22.1.5 Sales by Geography

22.1.6 Business Strategy

22.1.7 Key Information

22.1.8 SWOT Analysis

22.2 F. Hoffmann-La Roche

22.2.1 Key Facts

22.2.2 Business Overview

22.2.3 Business Segmentation

22.2.4 Business Segmentation by Revenue 2012 and 2013

22.2.5 Sales by Geography

22.2.6 Business Strategy

22.2.7 Key Information

22.2.8 SWOT Analysis

22.3 Gilead Sciences

22.3.1 Key Facts

22.3.2 Business Overview

22.3.3 Geographical Segmentation by Revenue 2013

22.3.4 Recent Developments

22.3.5 SWOT Analysis

22.4 Novartis

22.4.1 Key Facts

22.4.2 Business Description

22.4.3 Business Segmentation

22.4.4 Revenue by Business Segmentation

22.4.5 Revenue Comparison 2012 and 2013

22.4.6 Sales by Geography

22.4.7 Business Strategy

22.4.8 Key Developments

22.4.9 SWOT Analysis

22.5 Vertex Pharmaceuticals

22.5.1 Key Facts

22.5.2 Business Overview

22.5.3 Business Segmentation by Revenue 2013

22.5.4 Business Segmentation by Revenue 2012 and 2013

22.5.5 Geographical Segmentation by Revenue 2013

22.5.6 Business Strategy

22.5.7 Recent Developments

22.5.8 SWOT Analysis

23. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Snapshot of Cystic Fibrosis

Exhibit 3: Defects Caused by CFTR Mutation

Exhibit 4: Prevalence Rate of Cystic Fibrosis by Country 2014

Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014 (million)

Exhibit 6: Forecast for Prevalence of Cystic Fibrosis in UK 2014-2019 (million)

Exhibit 7: Age Distribution of Cystic Fibrosis Patients in UK at Death 2013 (in years)

Exhibit 8: Age Distribution of Cystic Fibrosis Patients in UK by Gender 2013

Exhibit 9: Age Distribution of Cystic Fibrosis Patients in UK by Sex 2013

Exhibit 10: Diagnosis of Cystic Fibrosis

Exhibit 11: Manifestations of Cystic Fibrosis

Exhibit 12: Snapshot of Economic Burden of Cystic Fibrosis

Exhibit 13: Pipeline Snapshot of Cystic Fibrosis Drugs

Exhibit 14: Cystic Fibrosis Market in Europe 2014-2019 (US$ million)

Exhibit 15: Segmentation of Cystic Fibrosis Market in Europe by Molecule Type

Exhibit 16: Cystic Fibrosis Market in Europe by Molecule Type 2014

Exhibit 17: Segmentation of Cystic Fibrosis Market in Europe by Route of Administration

Exhibit 18: Cystic Fibrosis Market in Europe by Route of Administration 2014

Exhibit 19: Segmentation of Cystic Fibrosis Market in Europe by Dosage Form

Exhibit 20: Cystic Fibrosis Market in Europe by Dosage Form 2014

Exhibit 21: Buying Criteria in Cystic Fibrosis Market in Europe

Exhibit 22: Drivers and their Impact on the Key Customer Category of the Cystic Fibrosis Market in Europe

Exhibit 23: Cystic Fibrosis Market in Europe Market Share Analysis 2014 

Exhibit 24: Global Sales of Pulmozyme 2012 and 2013 (US$ million)

Exhibit 25: Quarterly Global Sales of Pulmozyme 1994-2008 (US$ million)

Exhibit 26: Quarterly Sales of Pulmozyme to Collaborators 1997-2008 (US$ million)

Exhibit 27: TOBI Podhaler

Exhibit 28: Comparison of YoY Global Sales of TOBI and TOBI Podhaler 2006-2013 (US$ million)

Exhibit 29: Comparison of YoY Global Sales of Kalydeco 2012-2013 (US$ million)

Exhibit 30: Cystic Fibrosis Market in Europe Business Segmentation 2013

Exhibit 31: Cystic Fibrosis Market in Europe Business Segmentation by Revenue 2012 and 2013 (US$ million)

Exhibit 32: Actavis : Sales by Geography (in US$ million)

Exhibit 33: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013

Exhibit 34: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013

Exhibit 35: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)

Exhibit 36: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)

Exhibit 37: Gilead Sciences: Geographical Segmentation by Revenue 2013

Exhibit 38: Novartis AG: Business Segmentation

Exhibit 39: Novartis AG: Revenue by Business Segmentation 2013

Exhibit 40: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 41: Novartis AG: Revenue by Geographical Segmentation 2013

Exhibit 42: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013

Exhibit 43: Vertex Pharmaceuticals: Business Segmentation by Revenue  2012 and 2013 (US$ million)

Exhibit 44: Vertex Pharmaceuticals: Geographical Segmentation by Revenue 2013



Enquiry Before Buy